BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 9661069)

  • 1. Paget's disease of bone.
    Siris ES
    J Bone Miner Res; 1998 Jul; 13(7):1061-5. PubMed ID: 9661069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES; Lyles KW; Singer FR; Meunier PJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Paget's disease of bone.
    Langston AL; Ralston SH
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paget's disease of bone--current thinking and management.
    Hughes S; Peel-White AL; Peterson CK
    J Manipulative Physiol Ther; 1992 May; 15(4):242-9. PubMed ID: 1321871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial Paget's disease of bone: nonlinkage to the PDB1 and PDB2 loci on chromosomes 6p and 18q in a large pedigree.
    Good D; Busfield F; Duffy D; Lovelock PK; Kesting JB; Cameron DP; Shaw JT
    J Bone Miner Res; 2001 Jan; 16(1):33-8. PubMed ID: 11149487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
    Cremers SC; Eekhoff ME; Den Hartigh J; Hamdy NA; Vermeij P; Papapoulos SE
    J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
    O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
    J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates in the treatment of disorders of mineral metabolism.
    Singer FR; Minoofar PN
    Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of resistant Paget's disease of bone with pamidronate.
    Mallette LE
    Arch Intern Med; 1989 Dec; 149(12):2765-7. PubMed ID: 2596945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
    Chapurlat R; Meunier PJ
    Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease.
    Friedrichs WE; Reddy SV; Bruder JM; Cundy T; Cornish J; Singer FR; Roodman GD
    J Bone Miner Res; 2002 Jan; 17(1):145-51. PubMed ID: 11771661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Guidelines for improved therapeutic strategy in patients with Paget's osteitis deformans].
    Ringe JD; Reginster JY; Gennari C; Hosking DJ; Meunier PJ
    Z Rheumatol; 1996; 55(4):256-9. PubMed ID: 8967186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of Paget's disease].
    Kurth AA
    Orthopade; 2007 Feb; 36(2):118, 120-3. PubMed ID: 17252256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paget's disease of bone: diagnosis and treatment update.
    Noor M; Shoback D
    Curr Rheumatol Rep; 2000 Feb; 2(1):67-73. PubMed ID: 11123042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of Paget's disease based on viral etiology.
    Mirra JM
    Clin Orthop Relat Res; 1987 Apr; (217):162-70. PubMed ID: 3549089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.